Cite
HARVARD Citation
Hitz, F. et al. (2016). Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08. British journal of haematology. pp. 255-263. [Online].